United Therapeutics Corp. Stock Price, News & Analysis

United Therapeutics (NASDAQ:UTHR) announced that its TETON-2 pivotal study of Tyvaso® (treprostinil) Inhalation Solution for treating idiopathic pulmonary fibrosis (IPF) has met its primary endpoint. The study demonstrated a significant improvement in forced vital capacity (FVC) of 95.6 mL compared to placebo at 52 weeks (p<0.0001).

The treatment showed benefits across all subgroups and achieved statistical significance in key secondary endpoints, including time to first clinical worsening event, percent predicted FVC, quality of life measures, and lung diffusion capacity. The safety profile was consistent with previous studies, with no new safety concerns identified.

United Therapeutics plans to use data from both TETON-2 and the ongoing TETON-1 study to support a supplemental New Drug Application for IPF indication. TETON-1 results are expected in the first half of 2026.

United Therapeutics (Nasdaq: UTHR), a public benefit corporation, announced that CFO James Edgemond will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The presentation is scheduled for September 8, 2025, from 3:20 PM to 3:55 PM EST.

The session will be accessible through a live webcast on the company's investor relations website, with a recorded version available for 90 days after the event. As a unique publicly-traded biotech company structured as a public benefit corporation (PBC), United Therapeutics focuses on developing novel pharmaceutical therapies and technologies to expand transplantable organ availability.

United Therapeutics (NASDAQ:UTHR) has announced a significant $1 billion Accelerated Share Repurchase (ASR) program, structured through two $500 million agreements with Citibank - one collared and one uncollared. The company will make an upfront payment of $1 billion on August 4, 2025, receiving approximately 75% of shares under the uncollared agreement and 50% under the collared agreement initially.

The final settlement for the uncollared ASR is expected in Q4 2025, while the collared ASR will settle in Q1 2026. The repurchase program, authorized on July 30, 2025, demonstrates the company's confidence in its intrinsic value and upcoming catalysts. As of July 30, 2025, UTHR had approximately 45.2 million shares outstanding.

United Therapeutics (NASDAQ:UTHR) reported strong Q2 2025 financial results with record total revenue of $798.6 million, up 12% year-over-year, marking 12 consecutive quarters of double-digit growth. The company's Board authorized a $1 billion share repurchase program through March 2026.

Key highlights include Tyvaso DPI's record revenue of $315.2 million (22% growth), strong performance from Nebulized Tyvaso, Orenitram, and Unituxin. Net income reached $309.5 million ($6.41 per diluted share). The company expects continued double-digit revenue growth, supported by its commercial portfolio and late-stage pipeline in pulmonary fibrosis and pulmonary hypertension.

Important upcoming catalysts include the TETON 2 study results in September 2025 for idiopathic pulmonary fibrosis and ADVANCE OUTCOMES study data in H1 2026 for pulmonary arterial hypertension.

United Therapeutics (NASDAQ: UTHR) has scheduled its second quarter 2025 financial results announcement for Wednesday, July 30, 2025, before market open. The company will release detailed quarterly results via press release at approximately 6:30 a.m. Eastern Time, followed by a public webcast at 9:00 a.m. Eastern Time.

The webcast will be available through the company's investor relations website at ir.unither.com/events-and-presentations, with a rebroadcast accessible for one year afterward. United Therapeutics operates as a public benefit corporation (PBC), focusing on developing novel pharmaceutical therapies and technologies to expand transplantable organ availability.

United Therapeutics (NASDAQ:UTHR) and Intermountain Health have achieved a groundbreaking milestone with the world's first patient treatment using miroliverELAP®, a bioengineered external liver assist product. The procedure was performed at Intermountain Medical Center in Murray, Utah, on a patient with liver failure who wasn't eligible for transplant.

MiroliverELAP, developed by UTHR subsidiary Miromatrix Medical, consists of a single-use MIRO-001 bioengineered liver and extracorporeal blood circuit. The technology uses a decellularized porcine liver scaffold combined with human endothelial and liver cells. This Phase 1 study represents the first human clinical trial of a manufactured organ alternative, addressing a critical need as approximately 30% of acute liver failure patients die without access to liver transplants.

United Therapeutics (NASDAQ: UTHR) announced completion of enrollment for its phase 3 ADVANCE OUTCOMES study of ralinepag, a potential first-in-class once-daily oral prostacyclin agonist for pulmonary arterial hypertension (PAH). The study enrolled 728 participants, with top-line data expected in H1 2026. Previous phase 2 results showed promising efficacy with a 29.8% reduction in pulmonary vascular resistance compared to placebo. In the open-label extension study, ralinepag demonstrated sustained benefits, including a significant 36.3-meter improvement in six-minute walk distance and maintained stable functional class in over 85% of participants after two years. The drug also showed significant improvements in hemodynamic measures and maintained a manageable side effect profile.

United Therapeutics reported strong Q1 2025 financial results with total revenues reaching $794.4 million, marking a 17% increase from Q1 2024. The company's flagship product Tyvaso led growth with total revenues of $466.3 million, up 25% year-over-year.

Key highlights include net income of $322.2 million and earnings per diluted share of $6.63. Tyvaso DPI showed exceptional performance with a 33% revenue increase to $302.5 million. The growth was driven by increased patient numbers and Medicare Part D benefit redesign implementation.

The company announced progress in their organ transplant alternatives program, with planned FDA applications for UHeart and UThymoKidney products. They also expect results from the TETON 2 trial in idiopathic pulmonary fibrosis and plan to commence UKidney human clinical studies.

United Therapeutics (UTHR) has announced its participation in the American Thoracic Society (ATS) International Conference in San Francisco, May 16-21, 2025, where it will present clinical data across its commercial and development portfolio.

Key presentations include interim long-term data from the ralinepag phase 3 ADVANCE EXTENSION open-label study and preliminary baseline data from the TETON phase 3 studies of inhaled treprostinil in idiopathic pulmonary fibrosis. The company will showcase research through various sessions, including thematic posters, mini-symposia, and discussion sessions.

The company is also sponsoring several events including the Respiratory Innovation Summit, the ATS Research Program Benefit Networking Event, and hosting the Jenesis Innovative Research Awards™ Ceremony.